25I-NBMD: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Punct.
Flaming (talk | contribs)
3,466 edits
adding AFD
Line 1: Line 1:
<!-- Please do not remove or change this AfD message until the issue is settled -->
{{Article for deletion/dated|page=2C-TFM|timestamp=20120311062225|year=2012|month=March|day=11|substed=yes}}
<!-- For administrator use only: {{Old AfD multi|page=2C-TFM|date=11 March 2012|result='''keep'''}} -->
<!-- End of AfD message, feel free to edit beyond this point -->
{{Drugbox
{{Drugbox
| verifiedrevid = 452164662
| verifiedrevid = 452164662

Revision as of 06:22, 11 March 2012

25I-NBMD
Identifiers
  • 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-methylenedioxyphenyl)methyl]ethanamine
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H20INO4
Molar mass441.259 g/mol g·mol−1
3D model (JSmol)
  • c13OCOc3cccc1CNCCc(c(OC)cc2I)cc2OC
  • InChI=1S/C18H20INO4/c1-21-16-9-14(19)17(22-2)8-12(16)6-7-20-10-13-4-3-5-15-18(13)24-11-23-15/h3-5,8-9,20H,6-7,10-11H2,1-2H3 checkY
  • Key:NJNMIPDEUMTYNV-UHFFFAOYSA-N checkY
  (verify)

25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT2A receptor with a Ki of 0.049nM at the human 5HT2A receptor.[1][2][3] The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT2A receptor.[4] Common doses are reported to be between 500 Mcg and 1.5 mg, Although the low end of the dose response curve, is similar to LSD, being active at 500 Mcg, some reports show 1.5-2.0 mg being a low dose, making it up to four times less active then it's nbome counterpart 25I-NBOMe. As of January 2012 some vendors have started to stock the substance as a Designer drug. Due to the fact it is a research chemical and has not been on the open market for long there are very few reports about its use.

See also

References

  1. ^ Braden, MR; Parrish, JC; Naylor, JC; Nichols, DE (2006). "Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists". Molecular pharmacology. 70 (6): 1956–64. doi:10.1124/mol.106.028720. PMID 17000863.
  2. ^ Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.
  3. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1007/s00259-010-1686-8, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1007/s00259-010-1686-8 instead.
  4. ^ Isberg V, Balle T, Sander T, Jørgensen FS, Gloriam DE (2011). "G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations". Journal of Chemical Information and Modeling. 51 (2): 315–25. doi:10.1021/ci100402f. PMID 21261291. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)


Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=25I-NBMD&oldid=481284683"